• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Superconnector
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Zimmer Biomet Holdings Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

    11/5/25 6:30:25 AM ET
    $ZBH
    Industrial Specialties
    Health Care
    Get the next $ZBH alert in real time by email
    8-K
    false00011368690001136869zbh:ThreePointFiveOneEightPercentageNotesDueTwoThousandThirtyTwoMember2025-11-052025-11-050001136869us-gaap:CommonStockMember2025-11-052025-11-0500011368692025-11-052025-11-050001136869zbh:OnePointOneSixFourPercentageNotesDueTwoThousandTwentySevenMember2025-11-052025-11-050001136869zbh:TwoPointFourTwoFivePercentageNotesDueTwoThousandTwentySixMember2025-11-052025-11-05

     

     

    UNITED STATES
    SECURITIES AND EXCHANGE COMMISSION
    WASHINGTON, D.C. 20549

     

    FORM 8-K

     

    CURRENT REPORT

    Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

    Date of Report (Date of earliest event reported): November 5, 2025

     

     

    ZIMMER BIOMET HOLDINGS, INC.

    (Exact name of Registrant as Specified in Its Charter)

     

     

    Delaware

    001-16407

    13-4151777

    (State or Other Jurisdiction
    of Incorporation)

    (Commission File Number)

    (IRS Employer
    Identification No.)

     

     

     

     

     

    345 East Main Street

     

    Warsaw, Indiana

     

    46580

    (Address of Principal Executive Offices)

     

    (Zip Code)

     

    Registrant’s Telephone Number, Including Area Code: (574) 373-3333

     

    Not applicable

    (Former Name or Former Address, if Changed Since Last Report)

     

    Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

    ☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

    ☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

    ☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

    ☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

    Securities registered pursuant to Section 12(b) of the Act:


    Title of each class

     

    Trading
    Symbol(s)

     


    Name of each exchange on which registered

    Common Stock, $0.01 par value

     

    ZBH

     

    New York Stock Exchange

    2.425% Notes due 2026

     

    ZBH 26

     

    New York Stock Exchange

    1.164% Notes due 2027

     

    ZBH 27

     

    New York Stock Exchange

    3.518% Notes due 2032

     

    ZBH 32

     

    New York Stock Exchange

    Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

    Emerging growth company ☐

    If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

     

     


     

    Item 2.02 Results of Operations and Financial Condition.

     

    On November 5, 2025, Zimmer Biomet Holdings, Inc. (the “Company”) issued a press release reporting its financial results for the quarter ended September 30, 2025. A copy of the press release is attached as Exhibit 99.1 and the information set forth therein is incorporated herein by reference and constitutes a part of this report.

     

    The information contained in this Item 2.02, including Exhibit 99.1, is being furnished and shall not be deemed to be “filed” with the Securities and Exchange Commission for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”) or otherwise subject to the liabilities of that section and is not incorporated by reference into any filing of the Company under the Securities Act of 1933, as amended, or the Exchange Act, whether made before or after the date hereof, except as shall be expressly set forth by specific reference in such a filing.

     

     

    Item 9.01 Financial Statements and Exhibits.

     

    (d)
    Exhibits

     

    EXHIBIT INDEX

    Exhibit No.

     

    Description

    99.1

     

    Press release dated November 5, 2025

    104

     

    Cover Page Interactive Data File (embedded within the Inline XBRL document)

     

     


     

    SIGNATURES

    Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

    Dated: November 5, 2025

     

     

    ZIMMER BIOMET HOLDINGS, INC.

     

     

     

     

    By:

    /s/ Chad F. Phipps

     

    Name:

    Chad F. Phipps

     

    Title:

    Senior Vice President, General Counsel
    and Secretary

     

     

     

     


    Get the next $ZBH alert in real time by email

    Crush Q3 2025 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $ZBH

    DatePrice TargetRatingAnalyst
    11/6/2025$100.00Overweight → Neutral
    Analyst
    9/18/2025$130.00Buy
    Rothschild & Co Redburn
    7/15/2025$135.00Neutral → Buy
    Roth Capital
    12/17/2024$125.00 → $128.00Neutral → Overweight
    Analyst
    9/10/2024Peer Perform
    Wolfe Research
    7/1/2024$140.00 → $115.00Overweight → Neutral
    Piper Sandler
    5/30/2024$129.00Neutral
    Goldman
    5/21/2024$150.00Hold → Buy
    Argus
    More analyst ratings

    $ZBH
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Zimmer Biomet to Present at the Annual Jefferies Global Healthcare Conference in London

    WARSAW, Ind., Nov. 7, 2025 /PRNewswire/ -- Zimmer Biomet Holdings, Inc. (NYSE and SIX: ZBH), a global medical technology leader, today announced that members of the Zimmer Biomet management team will be presenting at the Annual Jefferies Global Healthcare Conference in London on Tuesday, Nov. 18, 2025, at Noon GMT (7 a.m. ET). A live webcast of the presentation can be accessed via Zimmer Biomet's Investor Relations website at https://investor.zimmerbiomet.com. The webcast will be archived for replay following the conference. About Zimmer BiometZimmer Biomet is a global medical

    11/7/25 7:30:00 AM ET
    $ZBH
    Industrial Specialties
    Health Care

    Zimmer Biomet Announces Third Quarter 2025 Financial Results

    Third quarter net sales of $2.001 billion increased 9.7% on a reported basis, 8.6% on a constant currency1 basis and 5.0% on an organic constant currency1 basisThird quarter diluted earnings per share were $1.16; adjusted1 diluted earnings per share were $1.90, an increase of 9.2%For full-year 2025, Company maintains reported revenue growth guidance, reflecting the latest currency expectations, and narrows constant currency1 and organic constant currency1 revenue growth guidanceWARSAW, Ind., Nov. 5, 2025 /PRNewswire/ -- Zimmer Biomet Holdings, Inc. (NYSE and SIX: ZBH) today reported financial results for the quarter ended September 30, 2025.  The Company reported third quarter net sales of $

    11/5/25 6:30:00 AM ET
    $ZBH
    Industrial Specialties
    Health Care

    Zimmer Biomet Announces FDA Breakthrough Designation for World's First Iodine-Treated Total Hip Replacement System

    Prioritized Regulatory Review Process in the U.S. Follows Japan PMDA Approval in September WARSAW, Ind., Oct. 28, 2025 /PRNewswire/ -- Zimmer Biomet Holdings, Inc. (NYSE and SIX: ZBH), a global medical technology leader, today announced the U.S. Food and Drug Administration (FDA) has granted Breakthrough Device Designation for the company's first-to-world iodine-treated total hip replacement system. This is the first product in Zimmer Biomet history to receive this designation. Iodine technology integrates a controlled-release iodine surface treatment into the iTaperloc® Compl

    10/28/25 7:30:00 AM ET
    $ZBH
    Industrial Specialties
    Health Care

    $ZBH
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 4 filed by Exec VP, CFO Upadhyay Suketu

    4 - ZIMMER BIOMET HOLDINGS, INC. (0001136869) (Issuer)

    11/3/25 5:42:29 PM ET
    $ZBH
    Industrial Specialties
    Health Care

    SEC Form 4 filed by Director Shapiro Louis

    4 - ZIMMER BIOMET HOLDINGS, INC. (0001136869) (Issuer)

    10/2/25 5:20:07 PM ET
    $ZBH
    Industrial Specialties
    Health Care

    SEC Form 4 filed by Director Kurdikar Devdatt

    4 - ZIMMER BIOMET HOLDINGS, INC. (0001136869) (Issuer)

    10/2/25 5:19:30 PM ET
    $ZBH
    Industrial Specialties
    Health Care

    $ZBH
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Jafry Syed A. bought $223,641 worth of shares (2,135 units at $104.75), increasing direct ownership by 111% to 4,060 units (SEC Form 4)

    4 - ZIMMER BIOMET HOLDINGS, INC. (0001136869) (Issuer)

    11/13/23 4:02:02 PM ET
    $ZBH
    Industrial Specialties
    Health Care

    Begley Christopher B bought $117,114 worth of shares (1,000 units at $117.11), increasing direct ownership by 39% to 3,540 units (SEC Form 4)

    4 - ZIMMER BIOMET HOLDINGS, INC. (0001136869) (Issuer)

    9/29/23 4:05:41 PM ET
    $ZBH
    Industrial Specialties
    Health Care

    $ZBH
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Zimmer Biomet downgraded by Analyst with a new price target

    Analyst downgraded Zimmer Biomet from Overweight to Neutral and set a new price target of $100.00

    11/6/25 8:47:26 AM ET
    $ZBH
    Industrial Specialties
    Health Care

    Rothschild & Co Redburn initiated coverage on Zimmer Biomet with a new price target

    Rothschild & Co Redburn initiated coverage of Zimmer Biomet with a rating of Buy and set a new price target of $130.00

    9/18/25 8:46:50 AM ET
    $ZBH
    Industrial Specialties
    Health Care

    Zimmer Biomet upgraded by Roth Capital with a new price target

    Roth Capital upgraded Zimmer Biomet from Neutral to Buy and set a new price target of $135.00

    7/15/25 8:30:57 AM ET
    $ZBH
    Industrial Specialties
    Health Care

    $ZBH
    SEC Filings

    View All

    SEC Form 10-Q filed by Zimmer Biomet Holdings Inc.

    10-Q - ZIMMER BIOMET HOLDINGS, INC. (0001136869) (Filer)

    11/5/25 4:06:05 PM ET
    $ZBH
    Industrial Specialties
    Health Care

    Zimmer Biomet Holdings Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

    8-K - ZIMMER BIOMET HOLDINGS, INC. (0001136869) (Filer)

    11/5/25 6:30:25 AM ET
    $ZBH
    Industrial Specialties
    Health Care

    SEC Form 8-K filed by Zimmer Biomet Holdings Inc.

    8-K - ZIMMER BIOMET HOLDINGS, INC. (0001136869) (Filer)

    10/7/25 4:10:58 PM ET
    $ZBH
    Industrial Specialties
    Health Care

    $ZBH
    Leadership Updates

    Live Leadership Updates

    View All

    Zimmer Biomet Announces New Chief Medical Advisors to Help Improve Standard of Musculoskeletal Care

    Dr. Jonathan M. Vigdorchik Named Chief Medical Technology Advisor, Adult Reconstruction and Hip Implants Dr. Anand M. Murthi Appointed Chief Medical Advisor, Shoulder, Sports, Extremities, and Trauma (S.E.T.) WARSAW, Ind., Aug. 28, 2025 /PRNewswire/ -- Zimmer Biomet Holdings, Inc. (NYSE and SIX: ZBH), a global medical technology leader, today announced the appointments of Jonathan M. Vigdorchik, MD, as Chief Medical Technology Advisor focused on Adult Reconstruction and Hip Implants, and Anand M. Murthi, MD, FAAOS, as Chief Medical Advisor, Shoulder, Sports, Extremities, and Trauma (S.E.T.). As strategic advisors, Drs. Vigdorchik and Murthi will leverage their extensive clinical experience t

    8/28/25 7:30:00 AM ET
    $ZBH
    Industrial Specialties
    Health Care

    Zimmer Biomet Appoints Kevin Thornal as Group President, Global Businesses and the Americas

    WARSAW, Ind., May 27, 2025 /PRNewswire/ -- Zimmer Biomet Holdings, Inc. (NYSE and SIX: ZBH), a global medical technology leader, today announced the appointment of Kevin Thornal as Group President, Global Businesses and the Americas. Reporting to Chairman-Elect, President and CEO Ivan Tornos, Mr. Thornal will join the Company on July 1, 2025 to oversee the Americas commercial organization and lead business strategy and execution for its global Knees, Hips, S.E.T. and Data, Technology, and Enabling Solutions units. "Kevin is an incredible addition to our leadership team at an e

    5/27/25 7:30:00 AM ET
    $ZBH
    Industrial Specialties
    Health Care

    Zimmer Biomet Names Kristen Cardillo as Senior Vice President, Chief Communications Officer

    WARSAW, Ind., March 6, 2025 /PRNewswire/ -- Zimmer Biomet Holdings, Inc. (NYSE and SIX: ZBH), a global medical technology leader, today announced the appointment of Kristen Cardillo as Senior Vice President, Chief Communications Officer. Reporting to President and CEO Ivan Tornos, Ms. Cardillo will join the Company on March 10, 2025, to lead Zimmer Biomet's global communications strategy, enhancing engagement with key stakeholders and amplifying the Company's position as a leader in MedTech. "Kristen's expertise in shaping compelling corporate narratives and leading high-impac

    3/6/25 7:30:00 AM ET
    $ZBH
    Industrial Specialties
    Health Care

    $ZBH
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G filed by Zimmer Biomet Holdings Inc.

    SC 13G - ZIMMER BIOMET HOLDINGS, INC. (0001136869) (Subject)

    11/14/24 1:22:34 PM ET
    $ZBH
    Industrial Specialties
    Health Care

    Amendment: SEC Form SC 13G/A filed by Zimmer Biomet Holdings Inc.

    SC 13G/A - ZIMMER BIOMET HOLDINGS, INC. (0001136869) (Subject)

    11/13/24 1:44:56 PM ET
    $ZBH
    Industrial Specialties
    Health Care

    SEC Form SC 13G filed by Zimmer Biomet Holdings Inc.

    SC 13G - ZIMMER BIOMET HOLDINGS, INC. (0001136869) (Subject)

    2/14/24 10:02:59 AM ET
    $ZBH
    Industrial Specialties
    Health Care

    $ZBH
    Financials

    Live finance-specific insights

    View All

    Zimmer Biomet Announces Third Quarter 2025 Financial Results

    Third quarter net sales of $2.001 billion increased 9.7% on a reported basis, 8.6% on a constant currency1 basis and 5.0% on an organic constant currency1 basisThird quarter diluted earnings per share were $1.16; adjusted1 diluted earnings per share were $1.90, an increase of 9.2%For full-year 2025, Company maintains reported revenue growth guidance, reflecting the latest currency expectations, and narrows constant currency1 and organic constant currency1 revenue growth guidanceWARSAW, Ind., Nov. 5, 2025 /PRNewswire/ -- Zimmer Biomet Holdings, Inc. (NYSE and SIX: ZBH) today reported financial results for the quarter ended September 30, 2025.  The Company reported third quarter net sales of $

    11/5/25 6:30:00 AM ET
    $ZBH
    Industrial Specialties
    Health Care

    Zimmer Biomet Completes Acquisition of Monogram Technologies

    Transaction creates the broadest, most flexible portfolio of orthopedic robotics and navigation technologies, including pathway towards the first fully autonomous robotic technology for orthopedic procedures  WARSAW, Ind., Oct. 7, 2025 /PRNewswire/ -- Zimmer Biomet Holdings, Inc. (NYSE and SIX: ZBH) ("Zimmer Biomet"), a global medical technology leader, today announced it has completed the acquisition of Monogram Technologies Inc. ("Monogram"), an AI-driven, next-generation orthopedic robotics company. Monogram's surgeon-guided semi- and fully autonomous robotic technologies a

    10/7/25 9:00:00 AM ET
    $ZBH
    Industrial Specialties
    Health Care

    Zimmer Biomet Announces Webcast and Conference Call of Third Quarter 2025 Financial Results

    WARSAW, Ind., Oct. 3, 2025 /PRNewswire/ -- Zimmer Biomet Holdings, Inc. (NYSE and SIX: ZBH) today announced its third quarter earnings conference call will be webcast on Wednesday, November 5, 2025 at 8:30 a.m. ET. A news release detailing the quarterly results will be made available that day at 6:30 a.m. ET. The live audio webcast can be accessed via Zimmer Biomet's Investor Relations website at https://investor.zimmerbiomet.com. It will be available for replay following the conference call. Individuals in the U.S. and Canada who wish to dial into the conference call may do s

    10/3/25 7:30:00 AM ET
    $ZBH
    Industrial Specialties
    Health Care